We analyzed the potential pharmaceuticals for group one and two druggable targets in DURGBANK database and found that LEFTY2 did not have corresponding drugs in PBC, while HSPB1 had three potential drugs: Apatorsen, Phenethyl Isothiocyanate, and Artenimol. The gene discussed is HSPB1; the disease is primary biliary cholangitis.